These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26286202)

  • 1. Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
    Ruof J; Flückiger O; Andre N
    Drugs R D; 2015 Sep; 15(3):221-6. PubMed ID: 26286202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.
    Ruof J; Knoerzer D; Dünne AA; Dintsios CM; Staab T; Schwartz FW
    Health Policy; 2014 Nov; 118(2):242-54. PubMed ID: 25194474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
    Staab T; Isbary G; Amelung VE; Ruof J
    BMC Health Serv Res; 2016 Nov; 16(1):651. PubMed ID: 27842592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.
    Dabisch I; Dethling J; Dintsios CM; Drechsler M; Kalanovic D; Kaskel P; Langer F; Ruof J; Ruppert T; Wirth D
    Health Econ Rev; 2014 Jan; 4(1):2. PubMed ID: 24460706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs.
    Niehaus I; Dintsios CM
    Health Policy; 2018 Jun; 122(6):599-606. PubMed ID: 29605527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data.
    Peinemann F; Labeit A
    J Evid Based Med; 2019 Feb; 12(1):9-15. PubMed ID: 30701688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY.
    Dintsios CM; Schlenkrich S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):196-204. PubMed ID: 29455689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
    Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
    Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life (HRQoL) in German early benefit assessment: The importance of disease-specific instruments.
    Kramer L; Moos M; Thaa B; Welte R; Esser M
    Z Evid Fortbild Qual Gesundhwes; 2024 May; 186():1-9. PubMed ID: 38580503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology.
    Serpas VJ; Raghav KP; Halperin DM; Yao J; Overman MJ
    BMC Med Res Methodol; 2018 Dec; 18(1):169. PubMed ID: 30541475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
    Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
    Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health related quality of life and endpoints in oncology].
    Bonnetain F
    Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
    Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
    Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
    Fischer KE; Heisser T; Stargardt T
    Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
    Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
    BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of Adjusted and Unadjusted Indirect Comparison Methods in Benefit Assessment. A Simulation Study for Time-to-event Endpoints.
    Kühnast S; Schiffner-Rohe J; Rahnenführer J; Leverkus F
    Methods Inf Med; 2017 May; 56(3):261-267. PubMed ID: 28361159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
    Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.